
, Nazihah Mohd Yunus1
, Aziati Azwari Annuar1
, Ahmad Aizat Abd. Aziz1
, Nurfadhlina Musa1
, Maruzairi Husain2
, Rowani Mohd Rawi3
1Human Genome Centre, School of Medical Sciences, Health Campus, Hospital Pakar Universiti Sains Malaysia, Kota Bharu, Malaysia
2Department of Psychiatry, School of Medical Sciences, Health Campus, Hospital Pakar Universiti Sains Malaysia, Kota Bharu, Malaysia
3Department of Paediatrics, School of Medical Sciences, Health Campus, Hospital Pakar Universiti Sains Malaysia, Kota Bharu, Malaysia
© 2026 Yeungnam University College of Medicine, Yeungnam University Institute of Medical Science
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conflicts of interest
No potential conflict of interest relevant to this article was reported.
Funding
This research was supported by a Universiti Sains Malaysia (USM), Short-Term Grant (grant No: R501-LR-RND002-0000000095-000).
Author contributions
Conceptualization: WNZ, NMY; Data curation: WNZ, AAA; Formal analysis: WNZ, AAAA; Funding acquisition: WNZ, NM, MH, RMR; Supervision: NMY; Validation: AAA, AAAA, NM, MH, RMR; Investigation: all authors; Writing-original draft: WNZ; Writing-review & editing: all authors.
APY, average publication years; FMRP, fragile X messenger ribonucleoprotein; FXS, fragile X syndrome; ASD, autism spectrum disorder; GABA, gamma-aminobutyric acid; NDD, neurodevelopmental disorders; mGluR, metabotropic glutamate receptor; FMR1, fragile X messenger ribonucleoprotein 1 gene; CGG, cytosine-guanine-guanine; ADHD, attention-deficit hyperactivity disorder; FRAXE, fragile X site E at Xq28 (CGG repeat expansion in the AFF2 gene); FRAXA, fragile X site A at Xq27.3 (CGG trinucleotide repeat expansion in the FMR1 gene).
| Rank | 1979–2013 | 2014–2026 | ||
|---|---|---|---|---|
| Author | TP | Author | TP | |
| 1 | Hagerman RJ (USA) | 42 | Roberts JE (USA) | 31 |
| 2 | Tassone F (USA) | 19 | Hagerman RJ (USA) | 27 |
| 3 | Khandjian EW (Canada) | 16 | Abbeduto L (USA) | 18 |
| 4 | Bardoni B (France) | 15 | Thurman AJ (USA) | 17 |
| 5 | Mandel JL (France) | 14 | Berry-Kravis EM (USA) | 17 |
| 6 | Warren ST (USA) | 14 | Klusek J (USA) | 15 |
| 7 | Hagerman PJ (USA) | 14 | Sterling A (USA) | 14 |
| 8 | Reiss AL (USA) | 14 | Hogan AL (USA) | 13 |
| 9 | Brown WT (USA) | 14 | Tassone F (USA) | 11 |
| 10 | Greenough WT, Broadie K, Hessl D (USA) | 12 | Losh M (USA) | 10 |
| Rank | 1979–2013 | 2014–2026 | ||
|---|---|---|---|---|
| Country | TP | Country | TP | |
| 1 | USA | 312 | USA | 235 |
| 2 | Canada | 54 | China | 45 |
| 3 | UK | 43 | France | 32 |
| 4 | France | 39 | UK | 30 |
| 5 | Italy | 28 | Canada | 25 |
| 6 | Germany | 22 | Italy | 24 |
| 7 | Australia | 21 | Germany | 14 |
| 8 | Belgium | 13 | Switzerland | 11 |
| 9 | Netherlands | 12 | Japan | 11 |
| 10 | Sweden/China | 12 | Spain | 10 |
| Cluster: Theme | 1979–2013 | 2014–2026 | Thematic evolution |
|---|---|---|---|
| Keyword (APY) | Keyword (APY) | ||
| Cluster 1: Synaptic function and molecular neurobiology | FMRP (2007.5), synapse (2008.0), synaptic plasticity (2007.1), hippocampus (2004.3), protein synthesis (2006.8), RNA-binding protein (2004.9), translation (2007.3), long-term depression (2008.3) | FXS (2018.9), ASD (2019.2), Down syndrome (2019.9), behavioral phenotypes (2018.1), mouse (2018.3), development (2018.7), language (2019.0), Rett syndrome (2019.0) | Early studies focused on the molecular role of FMRP and mechanisms of synaptic dysfunction. After 2014, the cluster expanded toward translational neuroscience, linking synaptic abnormalities with behavioral phenotypes, NDDs, and developmental outcomes. |
| Cluster 2: Genetics, NDD, and clinical phenotypes | FXS (2005.3), ASD (2006.3), intellectual disability (2010.1), behavioral phenotypes (2004.5), Down syndrome (2008.9), cognition (2009.0), working memory (2010.5), language (2011.0) | FMRP (2018.2), NDDs (2021.5), RNA binding (2019.7), GABA (2016.3), synaptic proteins (2017.0), hippocampus (2015.2), Alzheimer disease (2017.3), brain (2017.3) | The focus shifted from describing cognitive and developmental manifestations of FXS toward understanding shared biological mechanisms across neurodevelopmental and neurodegenerative disorders. The appearance of Alzheimer disease and broader NDD terminology suggest increased interdisciplinary integration. |
| Cluster 3: FMR1 genetics and experimental models | FMR1 (2006.6), mGluR (2009.0), development (2004.9), ADHD (2006.3), premutation (2007.7), CGG repeat (2008.3), GABA (2009.7) | FMR1 (2019.6), intellectual disability (2019.8), premutation (2016.7), CGG repeat (2016.6), genetic testing (2023.0), mitochondria (2017.8), genetic counseling (2020.7) | Research evolved from gene discovery and mechanistic hypotheses (e.g., mGluR theory) toward clinical genetics, carrier identification, genetic counseling, and precision medicine. The emergence of genetic testing as one of the newest keywords (APY 2023) highlights increasing clinical translation. |
| Cluster 4: Epidemiology, diagnosis, and behavioral outcomes | Mental retardation (2002.7), FRAXE (1999.5), FRAXA (1999.6), screening (2003.2), prenatal diagnosis (1989.8), epidemiology (1991.0), infantile autism (1987.3), prevalence (1997.3) | Anxiety (2019.1), ADHD (2019.6), eye tracking (2020.8), pragmatic language (2020.0), social anxiety (2020.4), depression (2020.3), executive function (2015.3), social attention (2021.7) | Earlier studies concentrated on diagnosis, epidemiology, and syndrome identification. Recent work increasingly emphasizes behavioral assessment, social cognition, psychiatric comorbidities, and digital/experimental assessment methods such as eye tracking. |
TP, total number of publications.
TP, total number of publications.
APY, average publication years; FMRP, fragile X messenger ribonucleoprotein; FXS, fragile X syndrome; ASD, autism spectrum disorder; GABA, gamma-aminobutyric acid; NDD, neurodevelopmental disorders; mGluR, metabotropic glutamate receptor;